Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00150410 · ClinicalTrials.gov registry record · Phase 3
Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 626
- Enrollment target
NCT00150410: Completed Phase 3 study, sponsored by Pfizer.
NCT00150410 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 626 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00150410, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 626 participants
- Enrollment target
Study Summary
* Whether a combination of three therapies - metformin and a sulfonylurea plus Exubera, an investigational drug, controls your diabetes at least as much as a triple combination therapy of metformin and a sulfonylurea plus Avandia, a Food and Drug Administration (FDA) approved drug. * Whether a combination of two therapies - metformin plus Exubera controls your diabetes at least as much as a as a triple combination therapy of metformin and a sulfonylurea plus Avandia.
Interventions
- DRUG Inhaled insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 626 participants |
| Start Date | 2003-01 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
What the finished NCT00150410 record still lists
NCT00150410 is an interventional study that assigns participants to a tested intervention. The registered 626 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 1 intervention - of which Inhaled insulin is the first listed.
NCT00150410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00150410 about?
NCT00150410 is a clinical study titled "Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose". * Whether a combination of three therapies - metformin and a sulfonylurea plus Exubera, an investigational drug, controls your diabetes at least as much as a triple combination therapy of metformin and a sulfonylurea plus Avandia, a Food and Drug Administration (FDA) approved drug. * Whether a combi...
What is the current status of trial NCT00150410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 626 participants. The study started on 2003-01. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00150410?
The interventions under investigation include: Inhaled insulin (DRUG).
Who is sponsoring clinical trial NCT00150410?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00150410's enrollment target sits among peer trials
626 586th of 2000 higher than 1,415 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia